AMLX Key Statistics, Chart & Performance
The current stock price of AMLX is 12.33 USD. In the past month the price decreased by -17.8%. In the past year, price increased by 218.61%.
AMLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.01 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.24B | ||
| MRK | MERCK & CO. INC. | 12.12 | 265.03B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.23B | ||
| ZTS | ZOETIS INC | 19.91 | 55.63B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 22.64B | ||
| VTRS | VIATRIS INC | 5.29 | 14.19B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.54 | 11.23B | ||
| CORT | CORCEPT THERAPEUTICS INC | 93.92 | 8.69B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About AMLX
Company Profile
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Company Info
AMYLYX PHARMACEUTICALS INC
43 Thorndike Street
Cambridge MASSACHUSETTS US
Employees: 123
Phone: 16176820917
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What does AMLX do?
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Can you provide the latest stock price for AMYLYX PHARMACEUTICALS INC?
The current stock price of AMLX is 12.33 USD. The price decreased by -1.28% in the last trading session.
What is the dividend status of AMYLYX PHARMACEUTICALS INC?
AMLX does not pay a dividend.
What is the ChartMill rating of AMYLYX PHARMACEUTICALS INC stock?
AMLX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the market capitalization of AMLX stock?
AMYLYX PHARMACEUTICALS INC (AMLX) has a market capitalization of 1.35B USD. This makes AMLX a Small Cap stock.
Who owns AMYLYX PHARMACEUTICALS INC?
You can find the ownership structure of AMYLYX PHARMACEUTICALS INC (AMLX) on the Ownership tab.
What is the Short Interest ratio of AMYLYX PHARMACEUTICALS INC (AMLX) stock?
The outstanding short interest for AMYLYX PHARMACEUTICALS INC (AMLX) is 12.69% of its float.
AMLX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AMLX. When comparing the yearly performance of all stocks, AMLX is one of the better performing stocks in the market, outperforming 97.28% of all stocks.
AMLX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMLX. AMLX has a great financial health rating, but its profitability evaluates not so good.
AMLX Financial Highlights
Over the last trailing twelve months AMLX reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 2.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.15% | ||
| ROE | -44.96% | ||
| Debt/Equity | 0 |
AMLX Forecast & Estimates
17 analysts have analysed AMLX and the average price target is 20.74 USD. This implies a price increase of 68.21% is expected in the next year compared to the current price of 12.33.
For the next year, analysts expect an EPS growth of 34.95% and a revenue growth -100% for AMLX